Previous Close | 1.5000 |
Open | 1.5400 |
Bid | 1.6400 x 3000 |
Ask | 1.7300 x 1000 |
Day's Range | 1.3400 - 1.5400 |
52 Week Range | 0.6600 - 1.9500 |
Volume | |
Avg. Volume | 95,323 |
Market Cap | 40.488M |
Beta (5Y Monthly) | 0.96 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.1000 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for CADL
NEEDHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024, in San Diego, CA. The presentation will describe the second candidate from the enLIGH
NEEDHAM, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for CAN-3110 -- a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate – for the treatment of pati
Approaching 6 anticipated data readouts across 3 platforms in 2024, including survival data in non-small cell lung cancer (NSCLC) and a potentially registrational phase 3 clinical trial in prostate cancerFocusing on strategic key value drivers and catalysts, as a follow up to positive initial clinical and biomarker data in hard-to-treat cancersAdvancing the immunotherapy field with next-generation investigational therapies at the intersection of advanced analytics, biology and vectorologyExecuti